TRIM32 promotes retinoic acid receptor α-mediated differentiation in human promyelogenous leukemic cell line HL60

Biochemical and Biophysical Research Communications

Volumn 417, Issue 1, 2012, Pages 594-600

  Sato, Tomonobu ^a   Okumura, Fumihiko ^a   Iguchi, Akihiro ^a   Ariga, Tadashi ^a   Hatakeyama, Shigetsugu ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

HL60; Promyelogenous leukemia; RAR ; TRIM32; Ubiquitin

Indexed keywords

PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; TRIPARTITE MOTIF PROTEIN 32; UNCLASSIFIED DRUG;

ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN HL 60; CONTROLLED STUDY; GENE CONTROL; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSCRIPTION INITIATION;

ANIMALS; ANTIGENS, CD11B; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION, LEUKEMIC; HL-60 CELLS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MICE; RECEPTORS, RETINOIC ACID; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; TRETINOIN;

EID: 84855757354     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.12.012     Document Type: Article

References (34)

1. Zhou G.B., Chen S.J., Chen Z. Acute promyelocytic leukemia: a model of molecular target based therapy. Hematology 2005, 10(Suppl. 1):270-280.
2. de The H., Lavau C., Marchio A., Chomienne C., Degos L., Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991, 66:675-684.
3. Carpentier Y., Mayer P., Bobichon H., Desoize B. Cofactors in in vitro induction of apoptosis in HL60 cells by all-trans retinoic acid (ATRA). Biochem. Pharmacol. 1998, 55:177-184.
4. Huang M.E., Ye Y.C., Chen S.R., Chai J.R., Lu J.X., Zhoa L., Gu L.J., Wang Z.Y. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988, 72:567-572.
5. Dokmanovic M., Chang B.D., Fang J., Roninson I.B. Retinoid-induced growth arrest of breast carcinoma cells involves co-activation of multiple growth-inhibitory genes. Cancer Biol. Ther. 2002, 1:24-27.
6. Rochette-Egly C., Chambon P. F9 embryocarcinoma cells: a cell autonomous model to study the functional selectivity of RARs and RXRs in retinoid signaling. Histol. Histopathol. 2001, 16:909-922.
7. Altucci L., Rossin A., Raffelsberger W., Reitmair A., Chomienne C., Gronemeyer H. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat. Med. 2001, 7:680-686.
8. de Lera A.R., Bourguet W., Altucci L., Gronemeyer H. Design of selective nuclear receptor modulators: RAR and RXR as a case study. Nat. Rev. Drug Discov. 2007, 6:811-820.
9. Zhu J., Gianni M., Kopf E., Honore N., Chelbi-Alix M., Koken M., Quignon F., Rochette-Egly C., de The H. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins. Proc. Natl. Acad. Sci. USA 1999, 96:14807-14812.
10. Spinella M.J., Freemantle S.J., Sekula D., Chang J.H., Christie A.J., Dmitrovsky E. Retinoic acid promotes ubiquitination and proteolysis of cyclin D1 during induced tumor cell differentiation. J. Biol. Chem. 1999, 274:22013-22018.
11. Clurman B.E., Sheaff R.J., Thress K., Groudine M., Roberts J.M. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev. 1996, 10:1979-1990.
12. Hershko A., Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 1998, 67:425-479.
13. Kopf E., Plassat J.L., Vivat V., de The H., Chambon P., Rochette-Egly C. Dimerization with retinoid X receptors and phosphorylation modulate the retinoic acid-induced degradation of retinoic acid receptors alpha and gamma through the ubiquitin-proteasome pathway. J. Biol. Chem. 2000, 275:33280-33288.
14. Gianni M., Bauer A., Garattini E., Chambon P., Rochette-Egly C. Phosphorylation by p38MAPK and recruitment of SUG-1 are required for RA-induced RAR gamma degradation and transactivation. EMBO J. 2002, 21:3760-3769.
15. A. Nakajima, S. Maruyama, M. Bohgaki, N. Miyajima, T. Tsukiyama, N. Sakuragi, S. Hatakeyama, Ligand-dependent transcription of estrogen receptor alpha is mediated by the ubiquitin ligase EFP, Biochem. Biophys. Res. Commun. 357 (2007) 245-251.
16. Miyajima N., Maruyama S., Bohgaki M., Kano S., Shigemura M., Shinohara N., Nonomura K., Hatakeyama S. TRIM68 regulates ligand-dependent transcription of androgen receptor in prostate cancer cells. Cancer Res. 2008, 68:3486-3494.
17. Kikuchi M., Okumura F., Tsukiyama T., Watanabe M., Miyajima N., Tanaka J., Imamura M., Hatakeyama S. TRIM24 mediates ligand-dependent activation of androgen receptor and is repressed by a bromodomain-containing protein, BRD7, in prostate cancer cells. Biochim. Biophys. Acta 2009, 1793:1828-1836.
18. Reymond A., Meroni G., Fantozzi A., Merla G., Cairo S., Luzi L., Riganelli D., Zanaria E., Messali S., Cainarca S., Guffanti A., Minucci S., Pelicci P.G., Ballabio A. The tripartite motif family identifies cell compartments. EMBO J. 2001, 20:2140-2151.
19. Meroni G., Diez-Roux G. TRIM/RBCC, a novel class of 'single protein RING finger' E3 ubiquitin ligases. Bioessays 2005, 27:1147-1157.
20. Nisole S., Stoye J.P., Saib A. TRIM family proteins: retroviral restriction and antiviral defence. Nat. Rev. Microbiol. 2005, 3:799-808.
21. Kudryashova E., Kudryashov D., Kramerova I., Spencer M.J. Trim32 is a ubiquitin ligase mutated in limb girdle muscular dystrophy type 2H that binds to skeletal muscle myosin and ubiquitinates actin. J. Mol. Biol. 2005, 354:413-424.
22. Liu Y., Lagowski J.P., Gao S., Raymond J.H., White C.R., Kulesz-Martin M.F. Regulation of the psoriatic chemokine CCL20 by E3 ligases Trim32 and Piasy in keratinocytes. J. Invest. Dermatol. 2010, 130:1384-1390.
23. Locke M., Tinsley C.L., Benson M.A., Blake D.J. TRIM32 is an E3 ubiquitin ligase for dysbindin. Hum. Mol. Genet. 2009, 18:2344-2358.
24. Kano S., Miyajima N., Fukuda S., Hatakeyama S. Tripartite motif protein 32 facilitates cell growth and migration via degradation of Abl-interactor 2. Cancer Res. 2008, 68:5572-5580.
25. Schwamborn J.C., Berezikov E., Knoblich J.A. The TRIM-NHL protein TRIM32 activates microRNAs and prevents self-renewal in mouse neural progenitors. Cell 2009, 136:913-925.
26. Frosk P., Weiler T., Nylen E., Sudha T., Greenberg C.R., Morgan K., Fujiwara T.M., Wrogemann K. Limb-girdle muscular dystrophy type 2H associated with mutation in TRIM32, a putative E3-ubiquitin-ligase gene. Am. J. Hum. Genet. 2002, 70:663-672.
27. Borg K., Stucka R., Locke M., Melin E., Ahlberg G., Klutzny U., Hagen M., Huebner A., Lochmuller H., Wrogemann K., Thornell L.E., Blake D.J., Schoser B. Intragenic deletion of TRIM32 in compound heterozygotes with sarcotubular myopathy/LGMD2H. Hum. Mutat. 2009, 30:E831-E844.
28. Chiang A.P., Beck J.S., Yen H.J., Tayeh M.K., Scheetz T.E., Swiderski R.E., Nishimura D.Y., Braun T.A., Kim K.Y., Huang J., Elbedour K., Carmi R., Slusarski D.C., Casavant T.L., Stone E.M., Sheffield V.C. Homozygosity mapping with SNP arrays identifies TRIM32, an E3 ubiquitin ligase, as a Bardet-Biedl syndrome gene (BBS11). Proc. Natl. Acad. Sci. USA 2006, 103:6287-6292.
29. Sato T., Okumura F., Kano S., Kondo T., Ariga T., Hatakeyama S. TRIM32 promotes neural differentiation through retinoic acid receptor-mediated transcription. J. Cell Sci. 2011, 124:3492-3502.
30. 3 exerts dose-dependent dual effects on APL cells. Blood 1997, 89:3345-3353.
31. Zhao J., Zhang Z., Vucetic Z., Soprano K.J., Soprano D.R. HACE1: a novel repressor of RAR transcriptional activity. J. Cell. Biochem. 2009, 107:482-493.
32. Jing X., Infante J., Nachtman R.G., Jurecic R. E3 ligase FLRF (Rnf41) regulates differentiation of hematopoietic progenitors by governing steady-state levels of cytokine and retinoic acid receptors. Exp. Hematol. 2008, 36:1110-1120.
33. Fang Y., Zhou X., Lin M., Ying M., Luo P., Zhu D., Lou J., Yang B., He Q. Inhibition of all-trans-retinoic acid-induced proteasome activation potentiates the differentiating effect of retinoid in acute myeloid leukemia cells. Mol. Carcinog. 2011, 50:24-35.
34. Jiang G., Albihn A., Tang T., Tian Z., Henriksson M. Role of Myc in differentiation and apoptosis in HL60 cells after exposure to arsenic trioxide or all-trans retinoic acid. Leuk. Res. 2008, 32:297-307.